0001683168-23-004102.txt : 20230613 0001683168-23-004102.hdr.sgml : 20230613 20230613164032 ACCESSION NUMBER: 0001683168-23-004102 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230613 DATE AS OF CHANGE: 20230613 EFFECTIVENESS DATE: 20230613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp. CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-484103 FILM NUMBER: 231011740 BUSINESS ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20111019 D 1 primary_doc.xml X0708 D LIVE 0001533040 Phio Pharmaceuticals Corp. 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA MASSACHUSETTS 01752 508-767-3861 DELAWARE RXi Pharmaceuticals Corp. RXi Pharmaceuticals Corp Corporation true Robert J Bitterman 257 Simarano Drive Suite 101 Marlborough MA MASSACHUSETTS 01752 Executive Officer Director Patricia A Bradford 257 Simarano Drive Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Geert Cauwenbergh 257 Simarano Drive Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Robert L Ferrara 257 Simarano Drive Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Jonathan E Freeman 257 Simarano Drive Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Curtis A Lockshin 257 Simarano Drive Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Biotechnology No Revenues 06b false 2023-06-02 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 3RD FLOOR NEW YORK NY NEW YORK 10022 IL ILLINOIS TX TEXAS false 10907728 2999373 7908355 The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b). false 3 400001 0 In connection with the registered direct offering concurrent with the private placement, the placement agent received $400,001 and warrants to purchase up to 70,094 shares of common stock exercisable at $5.35 per share. 0 false Phio Pharmaceuticals Corp. /s/ Robert Bitterman Robert Bitterman President and Chief Executive Officer 2023-06-13